Full Text | PDF

Int J Biol Sci 2019; 15(4):847-856. doi:10.7150/ijbs.30970 This issue Cite

Review

PCAT-1: A Novel Oncogenic Long Non-Coding RNA in Human Cancers

Tiefu Xiong^*, Jianfa Li^*, Fangfang Chen^✉, Fangting Zhang^✉

The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen 518036
*These authors have contributed equally to this work.

✉ Corresponding authors: Dr. Fangting Zhang, Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center, Shenzhen 518036, Telephone: (86) 0755-8392-3333, E-mail: fangtingzhangcom; Dr. Fangfang Chen, Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center, Shenzhen 518036, Telephone: (86) 0755-8392-3333, E-mail: ffchencom More

Abstract

Long non-coding RNAs (lncRNAs) are transcripts longer than 200 nucleotides (nts) without obvious protein coding potential. lncRNAs act as multiple roles in biological processes of diseases, especially carcinomas. Prostate cancer associated transcript-1 (PCAT-1) is an oncogenic lncRNA that identified by RNA-Sequence in prostate cancer. High expression of PCAT-1 is observed in different types of cancers, including prostate cancer, colorectal cancer, hepatocellular cancer and gastric cancer. High expressed PCAT-1 is correlated with poor overall survival. Furthermore, PCAT-1 regulates cancer cell proliferation, apoptosis, migration and invasion. Additionally, PCAT-1 is involved in EMT and Wnt/β-catenin-signaling pathway. In this review, we focus on the implication of PCAT-1 in human cancers.

Keywords: long non-coding RNA, PCAT-1, cancer, biomarker, therapeutic target

Citation styles

©2024 Ivyspring International Publisher. Terms of use